Stem Cell Research
TaiGen Initiates Phase I Trial of the Stem Cell Mobilizer TG-0054
Published in Law and Health Weekly, April 26th, 2008
TaiGen Biotechnology Co., Ltd. announced the enrollment for the TG-0054 phase I trial under an IND from the US FDA. TG-0054 is a potent and selective inhibitor for the binding of the chemokine cell-surface receptor CXCR4 to its ligand SDF-1 and efficiently mobilizes stem cells (CD34+) and endothelial progenitor cells (CD133+) from bone marrow into peripheral circulation in a mouse model. TG-0054 will initially be developed for the indication of stem cell transplantation in cancer patients.
The randomized, double-blinded, placebo-controlled, sequential ascending single intravenous dose study of TG-0054 will evaluate the safety, tolerability, pharmacokinetics and the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
More Articles from Law and Health Weekly
- Aggression
Research on aggression published by scientists at City University of New York - Aging
United Health Foundation and Aging with Dignity Win National Healthcare Consumer Advocacy Award for 500,000 Wishes Campaign - Alcoholism
New MedPredict Report Suggests Market for Alcoholism Therapies is Underestimated - Allergies
11th Annual 'Food Allergy Awareness Week' - Allergies
Epi-Ready(R) to Launch Wall-Mounted Storage Unit for Auto-Injectible Epinephrine - Allergies
Findings from J.R. Cornelissevermaat and co-researchers advance knowledge in allergies - More from this issue of Law and Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
